Get the full Thryv Therapeutics Inc. company profile
Access contacts, investors, buying signals & more
Thryv Therapeutics Inc. has raised $30.0M in Series B funding, with InClin as the sole listed investor.
The clinical-stage biotech is developing precision medicines for genetic arrhythmia syndromes and acquired cardiometabolic diseases, built around potent, highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).
In biotechnology, a promising scientific idea is only the beginning. Turning that idea into a viable business requires much more than capital.
From an investment and business operations perspective, I believe some of the most important factors are the strength of the science, the ability to reach meaningful clinical milestones, capital efficiency, and the team's ability to execute its strategy. A recent example that caught my attention is the $30 million Series B financing announced by Thryv Therapeutics. What I find particularly interes
Ondine Biomedical Inc.
Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens. The company has created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.
$13.3M Unknown
today
Specific Biologics
Specific Biologics' mission is to develop novel gene editing technologies to treat diseases at the genetic level in cells inside the body. We are actively developing a platform technology consisting of a dual-cleaving nuclease that can be safely delivered to cells for the treatment of various genetic diseases. This technology is designed to better exploit the cell's naturally occurring DNA repair pathways through enhanced repair or predictable deletions.
$35.0M Series a
Largest funding rounds in Biotechnology on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Shockwave Medical United States | Unknown | $13.1B | 2y ago |
| 2 |  NeuroEM Therapeutics United States | Unknown |
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  BionicM Japan | Series b | $4.5M | today |
| 2 | Xenter United States | Series b | $58.3M | today |
today
| $7.2B |
| 2y ago |
| 3 |  GRAIL United States | Unknown | $7.1B | 2y ago |
| 4 |  Illumina United States | Unknown | $7.1B | 2y ago |
| 5 |  RemeGen Biosciences United States | Grant | $5.6B | 9mo ago |
| 3 |  SweGaN AB Sweden | Series b | $14.0M | 1d ago |
| 4 | .png&w=3840&q=75) Equalum (Acquired by Google) United States | Series b | $18.0M | 1d ago |
| 5 |  Ozlo United States | Series b | $22.0M | 3d ago |
Contacts, investors, buying intent signals & tech stack.
Trusted by 200+ sales teams
InClin
Reach Thryv Therapeutics Inc.'s investors directly from your dashboard.
Start free trialBionicM
Recently received
Nanostine
Recently received
Biotts
Recently received
